Skip to main content
Equibles
RKDA logo

RKDA · Arcadia Biosciences, Inc. · Metrics

Track RKDA — free

Use RKDA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RKDA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.15 +0.01 (+5.52%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“With cash and cash equivalents of $4.2 million as of June 30, 2026, the Company believes that its existing cash and cash equivalents will not be sufficient to meet its anticipated cash requirements for at least the next 12 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”
View the 10-Q filed Aug 13, 2026
Market Cap
$349,335
Shares
2.41M
Volume · Oct 20 257.93K Avg daily vol (3M) 1.85M

RKDA metrics

79 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.15
Market cap
$349,335

Price action

20 metrics
Price change (1W)
-26.3%
Price change (30D)
-65.2%
Price change (3M)
-77.3%
Price change (6M)
-86.3%
Price change (YTD)
-92.3%
Price change (1Y)
-96.9%
Trailing year
Price change (5Y)
—
52-week high
$4.92
52-week low
$0.15
Change from 52-week high
-96.9%
Change from 52-week low
+5.5%
Annualized volatility
93.8%
Annualized volatility (3M)
111.6%
Beta
0.8
RSI (14D)
18.9
Price vs SMA 50
-61.8%
Price vs SMA 200
-86.1%
Avg volume (3M)
1.85M
Relative volume
0.1
Average dollar volume
$532,661

Company

3 metrics
Sector
Consumer Defensive
Industry
Packaged Foods
Shares outstanding
2.41M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 1,358.6%
P / book
0.6
reciprocal yield 181.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3,175.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
4.2×
reciprocal yield 24.1%
EV / revenue historical average (5Y)
4.2×
reciprocal yield 24.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-07

Profitability

9 metrics
Gross margin
34.6%
Operating margin
-80.2%
Trailing 12 months
Net margin
-233.7%
Gross profit (TTM)
$1.64M
Operating profit (TTM)
−$3.80M
Net income (TTM)
−$11.09M
Trailing 12 months
Diluted EPS (TTM)
$-4.55
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$2.62
Gross profit per diluted share (TTM)
$0.85
Operating profit per diluted share (TTM)
$-2.39
EBITDA per diluted share (TTM)
$-145.82
Net income per diluted share (TTM)
$-4.52
Operating cash flow per diluted share (TTM)
$-1.42
Free cash flow per diluted share (TTM)
$-3.44
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.06
Book value per share
$3.02

Growth

11 metrics
Revenue growth YoY
-0.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.75M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+118.9%
Year over year · more shares
Revenue CAGR (3Y)
-13.2%
Revenue CAGR (5Y)
-9.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-1,752.3%
Return on assets
-188.2%
Debt / equity
—
Current ratio
3.5
EBITDA (TTM)
−$19.58M
Free cash flow (TTM)
—
Quick ratio
2.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$4.18M
Total assets
$5.89M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.50M
Capital expenditures (TTM)
$0
R&D (TTM)
$0
SG&A (TTM)
$5.45M
Stock compensation (TTM)
$99,000
R&D / revenue
—
Stock compensation / revenue
2.1%

Ownership (13F)

9 metrics
13F filers
18
13F filer change QoQ
+1
Institutional ownership
8.8%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
7.8%
Private-fund adviser ownership
1.2%
Active holders' share change QoQ
-40.3%
Holder tenure
2.7
Price vs estimated holder cost
-42.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.7%

Short interest

3 metrics
Short interest
3.7%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1469443 CUSIP 039014303 13F (30d) 4 filings 4 filers Visit website Investor relations